MCID: GLS001
MIFTS: 46

Gliosarcoma malady

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Gliosarcoma

About this section
Sources:
10Disease Ontology, 45NIH Rare Diseases, 47Novoseek, 12DISEASES, 51Orphanet, 36MeSH, 65UMLS, 42NCIt, 59SNOMED-CT, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Gliosarcoma:

Name: Gliosarcoma 10 45 47 12 51 36 65
Glioblastoma with Sarcomatous Component 10
 
Sarcomatous Glioblastoma 45

Characteristics:

Orphanet epidemiological data:

51
gliosarcoma:
Inheritance: Not applicable; Age of onset: Adult

Classifications:



External Ids:

Disease Ontology10 DOID:3071
MeSH36 D018316
NCIt42 C3796
Orphanet51 251576
UMLS via Orphanet66 C0206726
UMLS65 C0206726

Summaries for Gliosarcoma

About this section
Wikipedia:68 Gliosarcoma is a rare type of glioma, a cancer of the brain that comes from glial, or supportive, brain... more...

MalaCards based summary: Gliosarcoma, also known as glioblastoma with sarcomatous component, is related to breast cancer and glioma. An important gene associated with Gliosarcoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways are Alzheimers Disease Pathway and Vemurafenib Pathway, Pharmacodynamics. Affiliated tissues include brain, bone and t cells, and related mouse phenotypes are no phenotypic analysis and pigmentation.

Related Diseases for Gliosarcoma

About this section

Diseases related to Gliosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 311)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer30.0CCND3, CDK4, EGFR, FGFR1, PTEN, RB1
2glioma29.8CDK4, EGFR, IDH1, MGMT, PTEN, RB1
3lung cancer29.5CDK4, EGFR, FGFR1, MGMT, NFKBIA, PPARG
4prostate cancer29.2CDK4, EGFR, FGFR1, NFKBIA, PTEN, RB1
5giant cell glioblastoma27.7CCND3, CDK4, EGFR, FGFR1, FGFR3, FREM2
6adult brainstem gliosarcoma12.4
7oligodactyly tetramelic postaxial10.7GFAP, MGMT
8alveoli adenoma10.6GFAP, TP53
9pineal gland astrocytoma10.6GFAP, TP53
10pilocytic astrocytoma of cerebellum10.6GFAP, MGMT, TP53
11ovarian mucinous cystadenofibroma10.6GFAP, TP53
12lymphatic system disease10.6EGFR, TP53
13syphilis10.6GFAP, TP53
14plagiocephaly and x-linked mental retardation10.6FGFR1, FGFR3
15hypothyroidism due to deficient transcription factors involved in pituitary development or function10.6GFAP, RB1, TP53
16flna-related periventricular nodular heterotopia10.6FGFR1, FGFR3
17anaplastic ganglioglioma10.5GFAP, PTEN
18vulvar benign neoplasm10.5EGFR, MGMT, TP53
19cerebellar medulloblastoma10.5GFAP, TP53
20childhood infratentorial neoplasm10.5GFAP, TP53
21mediastinal neurilemmoma10.5EGFR, SNAI2, TP53
22skin glomus tumor10.5GFAP, PTEN
23transient hypogammaglobulinemia of infancy10.5FGFR3, TP53
24sensory system cancer10.5GFAP, LZTR1, TP53
25pilocytic astrocytoma10.5IDH1, TP53
26congenital disorder of glycosylation, type if10.5GFAP, IDH1, TP53
27esophageal lipoma10.5CDK4, RB1
28subependymal giant cell astrocytoma10.5GFAP, IDH1, TP53
29mixed astrocytoma-ependymoma10.5IDH1, TP53
30lateral ventricle meningioma10.5GFAP, TP53
31renal tubular acidosis, distal, autosomal recessive10.5EGFR, GFAP, PTEN
32breast adenomyoepithelial adenosis10.5GFAP, IDH1, TP53
33hypogonadotropic hypogonadism-frontoparietal alopecia syndrome10.5EGFR, IDH1, TP53
34bronchitis10.5GFAP, IDH1, PTEN
35childhood pilocytic astrocytoma10.5GFAP, PTEN, TP53
36internal auditory canal lipoma10.5PTEN, RB1, TP53
37bronchogenic lung adenocarcinoma10.5EGFR, FGFR1, TP53
38proctitis10.5EGFR, MGMT, TP53
39colon small cell carcinoma10.5GFAP, IDH1, MGMT, TP53
40salivary gland adenoid cystic carcinoma10.5GFAP, IDH1, MGMT, TP53
41anaplastic plasmacytoma10.5IDH1, MGMT
42myxoid chondrosarcoma10.5CDK4, IDH1, RB1
43epithelioid sarcoma10.4CDK4, GFAP
44urinary tract papillary transitional cell benign neoplasm10.4FGFR3, TP53
45ovary neuroendocrine neoplasm10.4PTEN, TP53
46scrapie10.4FGFR3, TP53
47cervical non-keratinizing squamous cell carcinoma10.4EGFR, TP53
48fallopian tube carcinosarcoma10.4CDK4, RB1, TP53
49familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement10.4GFAP, IDH1
50larynx sarcoma10.4EGFR, PTEN, TP53

Graphical network of the top 20 diseases related to Gliosarcoma:



Diseases related to gliosarcoma

Symptoms for Gliosarcoma

About this section

Drugs & Therapeutics for Gliosarcoma

About this section

Drugs for Gliosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 372)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DonepezilapprovedPhase 3, Phase 2271120014-06-43152
Synonyms:
( inverted exclamation markA)-E 2020
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
120014-06-4
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC-6969
AC1L1FAE
AKOS000277311
Aricept
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
 
Donepezil
Donepezil (INN)
Donepezil Hydrochloride
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum5_001662
Spectrum_001664
TL8000531
UNII-8SSC91326P
2
LomustineapprovedPhase 3, Phase 17613010-47-43950
Synonyms:
(Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian]
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]
1-(2-Chloroethyl)-3-cyclohexylnitrosourea
13010-47-4
AC-10564
AC1L1H2T
AI3-52779
BRN 2125058
Belustine
Bristol Myers Squibb Brand of Lomustine
Bristol-Myers Squibb Brand of Lomustine
C9H16ClN3O2
CCNU
CCNU [Chloroethyl nitrosoureas]
CCRIS 860
CHEMBL514
CID3950
CINU
Cecenu
CeeNU
CeeNU (TN)
CeeNU, CCNU, Lomustine
Ceenu
Chloroethylcyclohexylnitrosourea
Cyclohexyl chloroethyl nitrosourea
D00363
D008130
DB01206
EINECS 235-859-2
FT-0083566
Gleostine
 
HMS2090A17
HSDB 6519
I06-0087
ICIG 1109
LS-728
Lomustina
Lomustina [INN-Spanish]
Lomustine
Lomustine (USAN/INN)
Lomustine [USAN:BAN:INN]
Lomustine medac Brand
Lomustinum
Lomustinum [INN-Latin]
MolPort-001-768-818
N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea
N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea
NCGC00167466-01
NCI-C04740
NCI60_041743
NCIMech_000220
NPFAPI-06
NSC 79037
NSC-79037
NSC79037
OR5087
RB 1509
Rhone Poulenc Rorer Brand of Lomustine
Rhone-Poulenc Rorer Brand of Lomustine
S1840_Selleck
SRI 2200
UNII-7BRF0Z81KG
WLN: L6TJ AMVNNO&2G
ZINC03831006
lomustine
medac Brand of Lomustine
3
Morphineapproved, investigationalPhase 385557-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
Infumorph
 
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morphine
nchembio.317-comp1
nchembio.64-comp1
4
Methylphenidateapproved, investigationalPhase 3364113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
Methyl phenidyl acetate
 
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate Hydrochloride
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Quillivant XR
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
5
Epoetin alfaapprovedPhase 3626113427-24-0
Synonyms:
Epogen
 
Erythropoietin precursor
Procrit
6
ProcarbazineapprovedPhase 3, Phase 2, Phase 168671-16-94915
Synonyms:
1-Methyl-2-(P-(isopropylcarbamoyl)benzyl)hydrazine
1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine
2-(P-Isopropylcarbamoylbenzyl)-1-methylhydrazine
2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine
366-70-1 (mono-hydrochloride)
4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide
4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
671-16-9
AC-4547
AC1L1J8E
Ambap671-16-9
BIDD:GT0183
BPBio1_001369
BRN 0958270
BSPBio_001244
Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)- (9CI)
C07402
C12H19N3O
CAS-366-70-1
CB 400-497
CCRIS 2389
CHEMBL1321
CID4915
D08423
DB01168
EINECS 211-582-2
HMS2090J09
HSDB 3250
I01-8931
IBZ
Ibenzmethyzin
Ibenzmethyzine
LS-7671
MBH
MIH
Matulane
MolPort-005-940-370
N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide
 
N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide
N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine
N-4-Isopropylcarbamoylbenzyl-n'-methylhydrazine
N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide
N-Isopropyl-P-(2-methylhydrazinomethyl)-benzamide
N-Isopropyl-alpha-(2-methylhydrazino)-P-toluamide
N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide
N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide
NCGC00016438-01
NCGC00016438-02
NCI60_041703
NCIOpen2_004074
NSC-77213
Natulan
Natulanar
P-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
PCX
Prestwick0_001112
Prestwick1_001112
Prestwick2_001112
Prestwick3_001112
Procarbazin
Procarbazin [German]
Procarbazina
Procarbazina [INN-Spanish]
Procarbazine (INN)
Procarbazine Monohydrochloride
Procarbazine [INN:BAN]
Procarbazine hydrochloride
Procarbazinum
Procarbazinum [INN-Latin]
Ro 4-6467
Ro 4-6467/1
SPBio_003112
SRI-10847
UNII-35S93Y190K
p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide
procarbazine
7
Vincristineapproved, investigationalPhase 3, Phase 1, Phase 28632068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
8
IsotretinoinapprovedPhase 3, Phase 2, Phase 11154759-48-25538, 5282379
Synonyms:
(13-cis)-Retinoate
(13-cis)-Retinoic acid
(13cis)-retinoic acid
(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
(2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
(7E,9E,11E,13Z)-retinoic acid
(7e,9e,11e,13Z)-Retinoic acid
13 Cis-Retinoic Acid
13 cis retinoic acid
13-RA
13-cis RA
13-cis retinoic acid
13-cis-Retinoate
13-cis-Retinoic acid
13-cis-Vitamin A acid
13-cis-Vitamin a acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid
4-09-00-02388 (Beilstein Handbook Reference)
4759-48-2
97950-17-9
AC-15388
AC1NQZZ4
Absorica
Accutane
Accutane (TN)
Ambap302-79-4
Amnesteem
BML2-E07
BPBio1_000080
BRD-K76723084-001-05-9
BRN 1885770
BSPBio_000072
BSPBio_001331
BSPBio_003345
CCRIS 4286
CHEBI:6067
CHEMBL547
CID5282379
CIP-Isotretinoin
CPD000471891
Claravis
Clarus
D00348
D015474
EINECS 225-296-0
EU-0101081
Epuris
HMS1361C13
HMS1568D14
HMS1791C13
HMS1921D08
HMS1989C13
HMS2092N07
HSDB 3929
IDI1_033801
Isotane
Isotretinoin
Isotretinoin (USP)
 
Isotretinoin Retinoic acid
Isotretinoin Zinc Salt, 13 cis Isomer
Isotretinoin Zinc Salt, 13-cis-Isomer
Isotretinoin [USAN:BAN:INN]
Isotretinoin [USAN:INN:BAN]
Isotretinoina
Isotretinoine
Isotretinoine [INN-French]
Isotretinoino
Isotretinoino [INN-Spanish]
Isotretinoinum
Isotretinoinum [INN-Latin]
Isotrex
LMPR01090021
LS-143465
Lopac0_001081
MLS001074662
MolPort-003-666-394
Myorisan
NCGC00094358-01
NCGC00094358-02
NCGC00094358-03
NCGC00094358-04
NCGC00094358-05
NCGC00094358-06
NCGC00094358-07
NCGC00094358-08
NCGC00094358-09
NCGC00094358-13
Neovitamin A acid
Neovitamin a acid
Prestwick2_000256
Prestwick3_000256
Prestwick_642
R 3255
R3255_SIGMA
Retinoate
Retinoic acid
Ro 4 3780
Ro 4-3780
Ro 43780
Ro-4-3780
Ro-43780
Roaccutan
Roaccutane
Roacutan
SAM002548955
SMR000471891
SPECTRUM1502013
Sotret
Sotret (TN)
Spectrum5_001795
Spectrum5_001937
Teriosal
UNII-EH28UP18IF
Zenatane
cis-RA
cis-Retinoate
cis-Retinoic acid
isotretinoino
9
Bevacizumabapproved, investigationalPhase 3, Phase 2, Phase 11875216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
10
Dacarbazineapproved, investigationalPhase 2, Phase 3, Phase 14114342-03-45351166
Synonyms:
(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
37626-23-6
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-c arboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4342-03-4
5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
5-(Dimethyltriazeno)-4-imidazolecarboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboximide
5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
94361-71-4
AC1NQXVV
AC1NS01W
AC1NS4BN
AI3-52825
BPBio1_000428
BRD-K35520305-001-07-8
BSPBio_000388
BSPBio_002091
Biocarbazin
Biocarbazine
Biocarbazine R
C6H10N6O
CAS-891986
CCRIS 190
CHEBI:4305
CHEMBL476
CID5281007
CID5351166
CID5353562
Carboxamide, Dimethyl Imidazole
D00288
D003606
D2390_SIGMA
D3634
DB00851
DIC
DTCI
DTIC
DTIC Dome
DTIC, DTIC-Dome, Dacarbazine
DTIC-Dome
DTICDome
DTIE
Dacarbazin
Dacarbazina
Dacarbazine
Dacarbazine (JAN/USP/INN)
Dacarbazine [USAN:INN:BAN:JAN]
Dacarbazino
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
 
Dacatic
Decarbazine
Deticene
Di-me-triazenoimidazolecarboxamide
Di-methyl-triazenoimidazolecarboxamide
Dimethyl Imidazole Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Dimethyltriazenoimidazolecarboxamide
DivK1c_000326
Dtic-Dome
Dtic-Dome (TN)
Dtic-dome (tn)
EINECS 224-396-1
HE1150000
HMS1569D10
HMS2090A20
HMS2091I20
HMS501A08
HSDB 3219
I06-2280
I14-1659
ICDMT
ICDT
IDI1_000326
Imidazole Carboxamide
Imidazole Carboxamide, Dimethyl
Imidazole carboxamide
KBio1_000326
KBio2_001364
KBio2_003932
KBio2_006500
KBio3_001311
KBioGR_000896
KBioSS_001364
LS-119
MLS001332543
MLS001332544
MolPort-003-666-153
MolPort-003-846-120
MolPort-006-709-420
NCGC00016986-01
NCGC00091861-01
NCGC00091861-02
NCGC00091861-03
NCGC00091861-04
NCI-C04717
NCI60_004053
NCIMech_000261
NINDS_000326
NIOSH/HE1150000
NPFAPI-05
NSC 45388
NSC-45388
NSC45388
Prestwick0_000574
Prestwick1_000574
Prestwick2_000574
Prestwick3_000574
Prestwick_904
S1221_Selleck
SMP2_000251
SMR000857131
SPBio_001075
SPBio_002607
SPECTRUM1500218
ST51014976
Spectrum2_001148
Spectrum3_000366
Spectrum4_000308
Spectrum5_000823
Spectrum_000884
UNII-7GR28W0FJI
WLN: T5M CNJ DVZ ENUNN1&1
dacarbazine
11
Leflunomideapproved, investigationalPhase 36275706-12-63899
Synonyms:
210165-51-8
4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl
4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl)
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide
5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide
5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide)
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide
5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
75706-12-6
A77 1486
AB00052389
AC-6796
AC1L1GYK
AC1Q2EVA
AKOS000265193
AP-501/42475599
Arava
Arava (TN)
Arava, Leflunomide
Aventis Behring Brand of Leflunomide
Aventis Brand of Leflunomide
Aventis Pharma Brand of Leflunomide
BIDD:PXR0189
BPBio1_000930
BRD-K78692225-001-03-9
BSPBio_000844
C045463
C07905
CAS-75706-12-6
CHEBI:6402
CHEMBL960
CID3899
D00749
DB01097
DivK1c_000916
EU-0100649
HMS1570K06
HMS1922M06
HMS2090O12
HMS502N18
HSDB 7289
HWA 486
HWA-486
Hoechst Brand of Leflunomide
I06-2131
IDI1_000916
KBio1_000916
KBio2_000802
KBio2_003370
KBio2_005938
KBioSS_000802
L 5025
L5025_SIGMA
 
LS-86580
Leflunomid
Leflunomida
Leflunomida [INN-Spanish]
Leflunomide
Leflunomide (JAN/USAN/INN)
Leflunomide [USAN:INN]
Leflunomidum
Leflunomidum [INN-Latin]
Lefunomide
Lefunomide [INN-Spanish]
Lefunomide [Inn-Spanish]
Lopac-L-5025
Lopac0_000649
MLS-0003109.0001
MLS000069648
MLS001076267
MolPort-002-345-613
N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide
NCGC00015610-01
NCGC00015610-02
NCGC00015610-03
NCGC00015610-07
NCGC00015610-12
NCGC00022625-03
NCGC00022625-04
NCGC00022625-05
NCGC00022625-06
NCGC00022625-07
NCGC00022625-08
NINDS_000916
NSC677411
Prestwick0_000772
Prestwick1_000772
Prestwick2_000772
Prestwick3_000772
Prestwick_87
RS-34821
S1247_Selleck
SMR000058209
SPBio_002783
SPECTRUM1503927
SU 101
SU 101 (pharmaceutical)
SU-101
SU101
Spectrum5_000850
Spectrum_000322
TL8005179
UNII-G162GK9U4W
ZINC00004840
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-P-toluidide
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
leflunomide
lefunamide
12
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
13
TrioxsalenapprovedPhase 3, Phase 1403902-71-45585
Synonyms:
2',4,8-Trimethylpsoralen
4,5',8-Trimethylpsoralen
4,8,5'-Trimethylpsoralen
6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
Trimethylpsoralen
Trioxisaleno
 
Trioxsalen
Trioxysalen
Trioxysalene
Trioxysalenum
Trisoralen
trimethylpsoralen
trioxysalen
trisoralen
14
Temozolomideapproved, investigationalPhase 3, Phase 2, Phase 166285622-93-15394
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
85622-93-1
AC-758
AC1L1K9B
BIDD:GT0204
BRN 5547136
Bio-0147
C047246
C6H6N6O2
CCRG 81045
CCRG-81045
CCRIS 8996
CHEBI:153686
CHEMBL810
CID5394
CPD000466338
D06067
DB00853
Essex brand of temozolomide
HMS2051O12
HMS2090B08
I06-0149
I14-1943
LS-80558
M B 39831
M & B 39831
M&B 39831
M&B-39831
 
M-39831
MB 39831
MLS000759447
MLS001424028
MLS002701861
Methazolastone
NCGC00167429-01
NCGC00167429-02
NCI60_003316
NSC 362856
NSC-362856
NSC362856
SAM001246636
SMR000466338
STK623541
Sch 52365
Sch-52365
Schering brand of temozolomide
Schering-Plough brand of temozolomide
TL8005593
TMZ
TMZ-Bioshuttle
Temodal
Temodal (TN)
Temodar
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide
Temozolomide (JAN/USAN/INN)
Temozolomide [INN:BAN]
Temozolomidum
Temozolomidum [Latin]
Témozolomide
UNII-YF1K15M17Y
ZINC01482184
m & b 39831
temozolomide
15
CarmustineapprovedPhase 3, Phase 2, Phase 1207154-93-82578
Synonyms:
1,3-BIS(CHLOROETHYL)-1-NITROSOUREA
1,3-Bis(.beta.-chloroethyl)-1-nitrosourea
1,3-Bis(2-chloroethyl)-1-nitrosourea
1,3-Bis(2-chloroethyl)nitrosourea
1,3-Bis(beta-chloroethyl)-1-nitrosourea
154-93-8
AC-10563
AC1L1DZQ
AI3-52216
BCNU
BCNU [Chloroethyl nitrosoureas]
BRN 2049744
Becenum
Becenun
Bi CNU
BiCNU
BiCNU (TN)
Bicnu
Bicnu (tn)
Bio-0118
Bis(2-chloroethyl)1-nitrosourea
Bis(2-chloroethyl)nitrosourea
Bis(chloroethyl)nitrosourea
Bis-N,N'-(chloroethyl)nitrosourea
Bischlorethylnitrosourea
Bischlorethylnitrosurea
Bischloroethyl nitrosourea
Bischloroethyl nitrosourea [Chloroethyl nitrosoureas]
Bischloroethylnitrosourea
C 0400
C0400_SIGMA
C5H11Cl2N3O2
CCRIS 810
CHEBI:3423
CHEMBL513
CID2578
Carmubris
Carmustin
Carmustina
Carmustina [INN-Spanish]
Carmustine
Carmustine (USAN/INN)
Carmustine [USAN:INN:BAN]
Carmustinum
Carmustinum [INN-Latin]
D002330
D00254
DB00262
DTI 015
DivK1c_000835
EINECS 205-838-2
 
EU-0100188
FDA 0345
FIVB
FT-0083563
Gliadel
Gliadel Wafer
Gliadel, BCNU, NSC-409962, Becenun, Carmustine
HMS2092J22
HMS502J17
I14-11976
IDI1_000835
KBio1_000835
KBio2_000745
KBio2_003313
KBio2_005881
KBioGR_001296
KBioSS_000745
LS-890
Lopac-C-0400
Lopac0_000188
MLS001333962
MolPort-003-665-505
N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA
N,N'-Bis(2-chloroethyl)-N-nitrosourea
NCGC00015204-01
NCGC00015204-02
NCGC00015204-06
NCGC00093665-01
NCGC00093665-02
NCGC00093665-03
NCGC00093665-04
NCI-C04773
NCI60_003931
NINDS_000835
NSC 409962
NSC-409962
NSC409962
Nitrumon
Prestwick_997
S1521_Selleck
SK 27702
SMR000058426
SRI 1720
STK624770
Spectrum4_000888
Spectrum5_000920
Spectrum_000265
UNII-U68WG3173Y
WLN: ONN2GVM2G
ZINC03830387
bis-chloroethylnitrosourea
carmustine
carmustine in ethanol
16
DopamineapprovedPhase 3, Phase 1308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
17
CyproheptadineapprovedPhase 315129-03-32913
Synonyms:
1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
129-03-3
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
41354-29-4
5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-20-08-00500 (Beilstein Handbook Reference)
AC1L1ER8
AKOS004119847
Axoprol
BIDD:GT0324
BPBio1_000096
BPBio1_000155
BRD-K28143534-001-01-4
BRD-K28143534-003-03-6
BRN 1685976
BSPBio_000086
Biomol-NT_000131
C06935
CAS-969-33-5
CCRIS 5232
CHEBI:4046
CHEMBL516
CID2913
CYPROHEPTADINE
Ciproheptadina
Ciproheptadina [INN-Spanish]
Ciprovit
Ciprovit (TN)
Cypoheptadine
Cyproheptadiene
Cyproheptadin
Cyproheptadine
Cyproheptadine (INN)
 
Cyproheptadine Hcl
Cyproheptadine Hydrochloride
Cyproheptadine [INN:BAN]
Cyproheptadinum
Cyproheptadinum [INN-Latin]
D07765
DB00434
Dibenzosuberonone/Cyproheptadine
Dihexazin
Dronactin
EINECS 204-928-9
Eiproheptadine
Glutodina
HMS2090P20
HSDB 3048
L001016
LS-114933
Lopac-C-6022
Lopac0_000246
MK 141
MolPort-002-507-777
NCGC00015252-01
NCGC00015252-02
NCGC00015252-03
NCGC00015252-09
NCGC00024293-02
NCGC00024293-04
NCGC00024293-05
Oprea1_498140
PDSP1_001229
PDSP2_001213
Periactin
Periactine
Periactinol
Prestwick0_000103
Prestwick1_000103
Prestwick2_000103
Prestwick3_000103
SPBio_002025
STK802098
Tocris-0996
UNII-2YHB6175DO
Viternum
nchembio.559-comp10
18
Histamine PhosphateapprovedPhase 390651-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
19
Tretinoinapproved, investigational, nutraceuticalPhase 3, Phase 2, Phase 1210302-79-45538, 444795
Synonyms:
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
.beta.-Retinoic acid
13497-05-7 (hydrochloride salt)
15-Apo-beta-caroten-15-oic acid
187175-63-9
1n4h
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
302-79-4
5300-03-8
56573-65-0
7005-78-9
9(Z)-Retinoic acid
9-cis-RA
A-Acido (Argentina)
A-Vitaminsyre
A-Vitaminsyre [Denmark]
AC-6824
AC1L9GWO
AC1Q1J2J
AGN 100335
AGN 192013
AKOS000280845
ALRT 1057
AT-RA
ATRA
Aberel
Aberela
Aberela [Norway]
Accutane Roche
Acid A Vit (Belgium, Netherlands)
Acid, Retinoic
Acid, Vitamin A
Acid, all-trans-Retinoic
Acid, beta-all-trans-Retinoic
Acid, trans-Retinoic
Acide retinoique (French)
Acide retinoique (French) (DSL)
Acide retinoique (french) (dsl)
Acnavit
Acnavit [Denmark]
Airol
Aknefug
Aknoten
Alitretinoin
All Trans Retinoic Acid
All Trans-Retinoic Acid
All-(E)-Retinoate
All-(E)-Retinoic acid
All-trans Retinoic Acid
All-trans-Retinoate
All-trans-Retinoic acid
All-trans-Tretinoin
All-trans-Vitamin A acid
All-trans-Vitamin A1 acid
Alltrans-retinoic acid
Amnesteem
Atra-IV
Atragen
Atralin
Avita
Avita (TN)
Avita Gel
Avitoin
Avitoin [Norway]
BAL4079
BIDD:GT0483
BIDD:PXR0081
BML2-E05
BPBio1_000082
BRN 2057223
BSPBio_000074
BSPBio_001500
Betarretin
C00777
CCRIS 3294
CCRIS 7098
CHEBI:15367
CHEMBL38
CID444795
CPD000058245
Claravis
Cordes VAS [Germany]
Cordes vas
D00094
D014212
DB00523
DB00755
DB00982
Dermairol
EINECS 206-129-0
EU-0101061
Effederm
Effederm [France]
Epi-aberel
Eudyna
HMS1361K22
HMS1568D16
HMS1791K22
HMS1921D14
HMS1989K22
HMS2089D20
HMS2092N11
HMS502N05
HSDB 2169
HSDB 7186
I04-0008
I14-2351
IDI1_000903
IDI1_033970
Isotretinoin Retinoic acid
L000833
LGD 100057
LMPR01090019
LS-1154
Lopac0_001061
Lsotretinoin
MLS000028588
MLS001076515
MLS002207234
MLS002222211
MolPort-000-883-857
NCGC00017280-06
NCGC00017280-17
NCGC00021808-04
 
NCGC00021808-05
NCGC00021808-06
NCGC00021808-07
NCGC00021808-09
NCGC00021808-14
NCGC00021808-15
NSC 122758
NSC-122758
NSC122758
Nexret
Obagi
PDT-002-002
Panretin Gel
Panretyn
Potassium Salt, Tretinoin
Prestwick2_000257
Prestwick3_000257
Prestwick_424
R 2625
R0064
R2625_SIGMA
REA
RETINOIC ACID, ALL TRANS
RETINOIC acid
Refissa
Renova
Renova (TN)
Retacnyl
Retin A
Retin A (TN)
Retin-A
Retin-A Micro
Retin-a
Retin-a Micro
Retinoate
Retinoic acid
Retinoic acid, all-trans- (8CI)
Retinova
Retionic Acid
Retionic acid
Retisol-A
Retisol-a
Ro 1-5488
S1653_Selleck
SAM002264647
SMR000058245
SPECTRUM1502016
SR-01000000239
SR-01000000239-14
ST057075
Salt, Tretinoin Potassium
Salt, Tretinoin Sodium
Salt, Tretinoin Zinc
Sodium Salt, Tretinoin
Solage
Sotret
Spectrum5_001746
Spectrum5_001933
Stieva-A
Stieva-a
Stieva-a Forte
TRETINON
Tretin M
Tretin m
Tretin-x
Tretin.x
Tretinoin
Tretinoin (JAN/USP/INN)
Tretinoin (TN)
Tretinoin 0.1% cream or placebo
Tretinoin Cream
Tretinoin Gel Microsphere
Tretinoin Potassium Salt
Tretinoin Sodium Salt
Tretinoin Zinc Salt
Tretinoin [USAN:INN:BAN]
Tretinoin/All-Trans Retinoic Acid
Tretinoina
Tretinoina [INN-Spanish]
Tretinoine
Tretinoine (French)
Tretinoine (french) (einecs)
Tretinoine [INN-French]
Tretinoino
Tretinoino [INN-Spanish]
Tretinoinum
Tretinoinum [INN-Latin]
Tretinx
Tri-Luma
Trétinoïne
UNII-1UA8E65KDZ
UNII-5688UTC01R
UPCMLD-DP097
Vesanoid
Vesanoid (TN)
Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin
Vesnaroid
Vitamin A acid
Vitinoin
WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1
Zinc Salt, Tretinoin
[3H]Retinoic acid
all trans-Retinoic acid
all-(E)-Retinoic acid
all-(e)-Retinoic acid
all-trans-Retinoic acid
all-trans-Tretinoin
all-trans-Vitamin A acid
all-trans-Vitamin A1 acid
all-trans-Vitamin a acid
all-trans-Vitamin a1 acid
all-trans-b-Retinoic acid
all-trans-beta-Retinoic acid
b-Retinoic acid
beta all trans Retinoic Acid
beta-Ra
beta-Retinoate
beta-Retinoic Acid
beta-Retinoic acid
beta-all-trans-Retinoic acid
bmse000562
nchembio.154-comp2
trans Retinoic Acid
trans-Retinoate
trans-Retinoic acid
tretinoin
tretinoin liposome
tretinoine (French) (EINECS)
20Angiogenesis InhibitorsPhase 3, Phase 2, Phase 13688
21
VeliparibPhase 2, Phase 3, Phase 18811960529
Synonyms:
ABT 888
 
ABT-888
Veliparib
veliparib
22O(6)-benzylguaninePhase 3, Phase 2, Phase 134
23Liver ExtractsPhase 3, Phase 2, Phase 13572
24Analgesics, OpioidPhase 32304
25Tubulin ModulatorsPhase 3, Phase 1, Phase 24279
26Angiogenesis Modulating AgentsPhase 3, Phase 2, Phase 13611
27Antibodies, MonoclonalPhase 3, Phase 2, Phase 12413
28MitogensPhase 3, Phase 2, Phase 11386
29Antineoplastic Agents, AlkylatingPhase 3, Phase 2, Phase 13406
30Immunologic FactorsPhase 3, Phase 1, Phase 218483
31ImmunoglobulinsPhase 3, Phase 2, Phase 14477
32AnestheticsPhase 37385
33Endothelial Growth FactorsPhase 3, Phase 2, Phase 1328
34AntibodiesPhase 3, Phase 2, Phase 14477
35AnalgesicsPhase 3, Phase 2, Phase 19358
36Cholinergic AgentsPhase 3, Phase 23243
37Cholinesterase InhibitorsPhase 3, Phase 2498
38Antineoplastic Agents, PhytogenicPhase 3, Phase 2, Phase 14294
39Anesthetics, GeneralPhase 32274
40Anesthetics, IntravenousPhase 31943
41Central Nervous System DepressantsPhase 3, Phase 2, Phase 110016
42Peripheral Nervous System AgentsPhase 3, Phase 2, Phase 118510
43Alkylating AgentsPhase 3, Phase 2, Phase 13582
44NarcoticsPhase 32709
45pancreatic polypeptidePhase 3, Phase 120
46Neurotransmitter AgentsPhase 3, Phase 2, Phase 114795
47HematoporphyrinsPhase 310
48Photosensitizing AgentsPhase 3, Phase 1, Phase 2374
49Central Nervous System StimulantsPhase 3, Phase 21721
50Nootropic AgentsPhase 3, Phase 2604

Interventional clinical trials:

(show top 50)    (show all 453)
idNameStatusNCT IDPhase
1S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or GliosarcomaCompletedNCT00017147Phase 3
2Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma MultiformeCompletedNCT00820963Phase 3
3Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
4E-MOSAIC Electronic Tool to Monitor SymptomsCompletedNCT00477919Phase 3
5Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain TumorsCompletedNCT00369785Phase 3
6High Light and Low Light Dose PDT in GliomaCompletedNCT00118222Phase 3
7Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant GliomaCompletedNCT00052455Phase 3
8Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00006353Phase 3
9Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With GliomaCompletedNCT00003916Phase 3
10SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma MultiformeCompletedNCT00003293Phase 3
11Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma MultiformeCompletedNCT00002545Phase 3
12Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeRecruitingNCT02152982Phase 2, Phase 3
13Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaActive, not recruitingNCT00304031Phase 3
14Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT01480479Phase 3
15Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT00884741Phase 3
16Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingNCT00482677Phase 3
17Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial GliomasActive, not recruitingNCT00003788Phase 3
18Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for CancerTerminatedNCT01132547Phase 3
19Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain TumorsTerminatedNCT00031798Phase 3
20Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant GliomasWithdrawnNCT00003564Phase 3
21Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or GliosarcomaCompletedNCT00525525Phase 2
22Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and GliosarcomasCompletedNCT00597402Phase 2
23Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and GliosarcomasCompletedNCT00612339Phase 2
24Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00335764Phase 1, Phase 2
25Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain TumorsCompletedNCT00187486Phase 2
26Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) PatientsCompletedNCT00402116Phase 1, Phase 2
27Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00165477Phase 2
28Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma MultiformeCompletedNCT00979017Phase 2
29Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or GliosarcomaCompletedNCT00433381Phase 2
30Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00305864Phase 1, Phase 2
31GW572016 to Treat Recurrent Malignant Brain TumorsCompletedNCT00107003Phase 2
32AMG 102 and Avastin for Recurrent Malignant GliomaCompletedNCT01113398Phase 2
33BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)CompletedNCT01856933Phase 2
34Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)CompletedNCT00671970Phase 2
35Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)CompletedNCT00615927Phase 2
36Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + IrinotecanCompletedNCT00613028Phase 2
37Ph II Bevacizumab + Etoposide for Pts w Recurrent MGCompletedNCT00612430Phase 2
38Phase II Avastin + Bortezomib for Patients With Recurrent Malignant GliomaCompletedNCT00611325Phase 2
39Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma MultiformeCompletedNCT00672243Phase 2
40Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine GliomaCompletedNCT00028795Phase 2
41Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain TumorsCompletedNCT01836549Phase 2
42BIBF 1120 for Recurrent High-Grade GliomasCompletedNCT01380782Phase 2
43A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade GliomasCompletedNCT00995007Phase 2
44Tandutinib Plus Bevacizumab to Treat Recurrent Brain TumorsCompletedNCT00667394Phase 2
45Dose-Intense Temozolomide in Recurrent GlioblastomaCompletedNCT00657267Phase 2
46Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive MeningiomaCompletedNCT00354913Phase 2
47GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by SurgeryCompletedNCT00980343Phase 2
48Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma MultiformeCompletedNCT00641706Phase 2
49Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00540722Phase 2
50Sunitinib in Treating Patients With Recurrent Malignant GliomasCompletedNCT00499473Phase 2

Search NIH Clinical Center for Gliosarcoma


Cochrane evidence based reviews: gliosarcoma

Genetic Tests for Gliosarcoma

About this section

Anatomical Context for Gliosarcoma

About this section

MalaCards organs/tissues related to Gliosarcoma:

33
Brain, Bone, T cells, Bone marrow, Liver, Prostate, Kidney

Animal Models for Gliosarcoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Gliosarcoma:

38 (show all 27)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000301210.0EGFR, FGFR1, FGFR3, MGMT, PPARG, RB1
2MP:00011869.9CDK4, EGFR, FREM2, PTEN, RB1, SNAI2
3MP:00053719.9EGFR, FGFR1, FGFR3, FREM2, PTEN, RB1
4MP:00053709.8CCND3, CDK4, EGFR, PPARG, PTEN, RB1
5MP:00053889.8CCND3, EGFR, FGFR3, FREM2, IDH1, PTEN
6MP:00053679.7CDK4, EGFR, FGFR1, FGFR3, FREM2, PPARG
7MP:00020069.6CCND3, CDK4, EGFR, FGFR3, MGMT, PPARG
8MP:00053819.6CDK4, EGFR, FGFR1, FGFR3, GFAP, PTEN
9MP:00053779.6EGFR, FGFR1, FGFR3, FREM2, PPARG, RB1
10MP:00053809.6CDK4, EGFR, FGFR1, FREM2, PPARG, PTEN
11MP:00053829.6EGFR, FGFR1, FGFR3, FREM2, LZTR1, RB1
12MP:00053899.5CDK4, EGFR, FGFR1, FGFR3, FREM2, PPARG
13MP:00053699.5CDK4, EGFR, FGFR1, FREM2, GFAP, PPARG
14MP:00107719.4CDK4, EGFR, FGFR1, FGFR3, FREM2, NFKBIA
15MP:00053849.3CDK4, EGFR, FGFR1, FGFR3, GFAP, NFKBIA
16MP:00028739.3CCND3, CDK4, EGFR, FGFR1, FGFR3, GFAP
17MP:00053799.3CCND3, CDK4, EGFR, FGFR1, MGMT, NFKBIA
18MP:00053869.3CCND3, CDK4, FGFR1, FGFR3, GFAP, PPARG
19MP:00036319.3CDK4, EGFR, FGFR1, FGFR3, FREM2, GFAP
20MP:00053919.2CCND3, CDK4, EGFR, FGFR1, FGFR3, FREM2
21MP:00053909.0EGFR, FGFR1, FGFR3, FREM2, IDH1, PPARG
22MP:00053859.0CCND3, CDK4, EGFR, FGFR1, FREM2, GFAP
23MP:00053768.7CCND3, CDK4, EGFR, FGFR1, FGFR3, GFAP
24MP:00053788.6CCND3, CDK4, EGFR, FGFR1, FGFR3, FREM2
25MP:00053878.5CCND3, CDK4, EGFR, FGFR1, FGFR3, GFAP
26MP:00107688.4CCND3, CDK4, EGFR, FGFR1, FGFR3, FREM2
27MP:00053978.3CCND3, CDK4, EGFR, FGFR1, FGFR3, IDH1

Publications for Gliosarcoma

About this section

Articles related to Gliosarcoma:

(show top 50)    (show all 322)
idTitleAuthorsYear
1
Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A. (26082621)
2015
2
Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines. (25929336)
2015
3
CYP19A1 gene polymorphisms and risk of lung cancer. (23669293)
2013
4
Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. (24001336)
2013
5
Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice. (24301648)
2013
6
Pfit is a structurally novel Crohn's disease-associated superantigen. (24385909)
2013
7
Lower esophageal sphincter-preserving laparoscopy-assisted proximal gastrectomy in patients with early gastric cancer: a method for the prevention of reflux esophagitis. (23065041)
2013
8
ZNF365 promotes stability of fragile sites and telomeres. (23776040)
2013
9
Acute leukemic appendicitis in a patient with acute promyelocytic leukemia. (22531533)
2012
10
Increased type II deiodinase protein in OA-affected cartilage and allelic imbalance of OA risk polymorphism rs225014 at DIO2 in human OA joint tissues. (22492780)
2012
11
Identification of the peripheral blood levels of interleukin-12, interleukin-10, and transforming growth factor-I^ in patients with laryngeal squamous cell carcinoma. (21472884)
2012
12
Psychosis and temporal lobe epilepsy-role of electroconvulsive therapy. (22729342)
2012
13
Rickets. (21730812)
2011
14
Increased production of a proliferation-inducing ligand (APRIL) by peripheral blood mononuclear cells is associated with antitopoisomerase I antibody and more severe disease in systemic sclerosis. (20810514)
2010
15
Septic sacroiliitis: an uncommon septic arthritis. (20149323)
2009
16
Familial 4.3 Mb duplication of 21q22 sheds new light on the Down syndrome critical region. (21686961)
2009
17
Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. (19801529)
2009
18
Multicentric hyaline-vascular Castleman's disease treated by laparoscopic resection. (19298351)
2009
19
The utility of PU.1 as an immunohistochemical marker for histiocytic and dendritic lesions of the skin. (19542915)
2009
20
Chronic kidney disease in the VACTERL association: clinical course and outcome. (19172300)
2009
21
Development of a size exclusion chromatography-electrochemical detection method for the analysis of total organic and inorganic chloramines. (18718133)
2008
22
A case of diastematomyelia associated with hamartoma masquerading as meningocele in the newborn infant. (18097200)
2008
23
Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization. (18673574)
2008
24
The misdiagnosis of craniosynostosis as deformational plagiocephaly. (18216678)
2008
25
Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. (17234759)
2007
26
Posttransplant acidosis and associated disorders of mineral metabolism in patients with a renal graft. (17998871)
2007
27
YKL-40 in human lumbar herniated disc and its relationships with nitric oxide and cyclooxygenase-2. (17631744)
2007
28
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. (17128209)
2006
29
GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner. (16446369)
2006
30
Cerebral perfusion during off-pump coronary artery bypass grafting. (15170545)
2004
31
CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation in BxPC3 pancreatic adenocarcinoma cells. (15047698)
2004
32
Molecular mechanisms of brain tumor edema. (15561416)
2004
33
TGFbeta1 activates c-Jun and Erk1 via alphaVbeta6 integrin. (14572313)
2003
34
Novel cyclic and linear oligopeptides that bind to integrin beta1 chain and either inhibit or costimulate T lymphocytes. (12639821)
2003
35
Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11. (12239155)
2002
36
Absence of mutations in the beta-catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas. (11696170)
2001
37
Pleomorphic lipoma: case report and literature review. (10759828)
2000
38
Assignment of a disintegrin and metalloproteinase domain 10 (Adam10) gene to mouse chromosome 9. (9441766)
1997
39
Thymidylate synthase in advanced gastrointestinal and breast cancers. (8695163)
1996
40
Rational design of an animal model for Alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent. (8744398)
1996
41
Is polyhydramnios in an ultrasonographically normal fetus an indication for genetic evaluation? (7503195)
1995
42
Localization of NADPH-diaphorase activity in the pancreatic ganglia of the young chick. (7756748)
1995
43
A critical mutation in both WT1 alleles is not sufficient to cause Wilms' tumor. (7875294)
1995
44
Analysis of germline and in vivo somatic mutations in the human adenine phosphoribosyltransferase gene: mutational hot spots at the intron 4 splice donor site and at codon 87. (7685481)
1993
45
Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis. (7506428)
1993
46
Tumor necrosis factor (TNF) up-regulates the expression of p75 but not p55 TNF receptors, and both receptors mediate, independently of each other, up-regulation of transforming growth factor alpha and epidermal growth factor receptor mRNA. (8381414)
1993
47
Dissection of calbindin D9k into two Ca(2+)-binding subdomains by a combination of mutagenesis and chemical cleavage. (1544446)
1992
48
Focal acantholytic dyskeratosis occurring in pityriasis rubra pilaris. (2393436)
1990
49
Infantile hypertrophic pyloric stenosis--congenital or acquired? (7077061)
1982
50
Herpes zoster with a varicelliform eruption and parotitis in chronic leukemia. (14794487)
1951

Expression for genes affiliated with Gliosarcoma

About this section
Search GEO for disease gene expression data for Gliosarcoma.

Pathways for genes affiliated with Gliosarcoma

About this section

Pathways related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 37)
idSuper pathwaysScoreTop Affiliating Genes
110.2EGFR, FGFR1, FGFR3
210.2EGFR, FGFR1, FGFR3
310.1FGFR1, FGFR3, GFAP
410.1EGFR, FGFR1, SNAI2
510.0CCND3, CDK4, TP53
610.0CCND3, CDK4, RB1
7
Show member pathways
10.0CCND3, CDK4, RB1
810.0NFKBIA, TACC1, TACC3, TP53
910.0FGFR1, FGFR3, GFAP, SNAI2
10
Show member pathways
9.9CCND3, NFKBIA, PTEN, TP53
11
Show member pathways
9.9EGFR, FGFR1, FGFR3, NFKBIA, TP53
129.9CCND3, CDK4, NFKBIA, TP53
13
Show member pathways
9.9CCND3, CDK4, RB1, TP53
149.9CCND3, CDK4, RB1, TP53
159.9CCND3, CDK4, RB1, TP53
16
Show member pathways
9.9EGFR, FGFR1, FGFR3, PTEN, TP53
17
Show member pathways
9.9EGFR, FGFR1, FGFR3, PTEN, TP53
18
Show member pathways
9.8CDK4, PTEN, RB1, TP53
19
Show member pathways
9.8CDK4, PTEN, RB1, TP53
209.8CDK4, EGFR, FGFR3, RB1, TP53
219.8CDK4, EGFR, GFAP, RB1, TP53
22
Show member pathways
9.8CDK4, EGFR, NFKBIA, RB1, TP53
239.8EGFR, PTEN, RB1, SNAI2, TP53
24
Show member pathways
9.7EGFR, PTEN, RB1, SNAI2, TP53
259.7CDK4, EGFR, PTEN, RB1, TP53
269.7EGFR, FGFR1, FGFR3, IDH1, PTEN, TP53
279.7CCND3, CDK4, NFKBIA, RB1, TP53
289.7CCND3, CDK4, NFKBIA, RB1, TP53
29
Show member pathways
9.7CCND3, CDK4, PTEN, RB1, TP53
309.7CDK4, NFKBIA, PTEN, RB1, TP53
319.7CDK4, EGFR, FGFR1, NFKBIA, PTEN, TP53
329.6CDK4, EGFR, MGMT, PTEN, RB1, TP53
339.6CCND3, CDK4, EGFR, FGFR1, FGFR3, PTEN
34
Show member pathways
9.5CDK4, EGFR, FGFR1, NFKBIA, PTEN, RB1
35
Show member pathways
9.4CCND3, CDK4, EGFR, FGFR1, FGFR3, PTEN
369.2CDK4, EGFR, FGFR1, FGFR3, NFKBIA, PPARG
37
Show member pathways
9.0CCND3, CDK4, EGFR, FGFR1, FGFR3, GFAP

GO Terms for genes affiliated with Gliosarcoma

About this section

Cellular components related to Gliosarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1PML bodyGO:001660510.0PTEN, RB1, TP53

Biological processes related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of phospholipase activityGO:001051810.8FGFR1, FGFR3
2cellular response to ionizing radiationGO:007147910.6MGMT, SNAI2, TP53
3salivary gland morphogenesisGO:000743510.6EGFR, FGFR1
4phosphatidylinositol-mediated signalingGO:004801510.4EGFR, FGFR1, FGFR3, PTEN
5negative regulation of telomerase activityGO:005197410.4PPARG, TP53
6Ras protein signal transductionGO:000726510.2EGFR, FGFR1, FGFR3, RB1
7response to organic cyclic compoundGO:001407010.1IDH1, MGMT, PTEN
8positive regulation of cell proliferationGO:00082849.8CDK4, FGFR1, FGFR3, PTEN
9negative regulation of apoptotic processGO:00430669.8EGFR, NFKBIA, PTEN, SNAI2, TP53
10regulation of cell cycleGO:00517269.7CDK4, PTEN, RB1

Sources for Gliosarcoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet